MedTrace Logo

Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients

NCT00902031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-04-20

No results posted yet for this study

Summary

The purpose of this study is to determine if docusate is effective in the treatment of constipation in palliative care patients.

Conditions

Interventions

DRUG

Docusate Sodium, Sennoside

Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days. Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.

DRUG

Sennoside + Placebo

Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days. Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days

Sponsors & Collaborators

  • College of Family Physicians of Canada

    collaborator OTHER

  • Covenant Health, Canada

    collaborator OTHER

  • Capital Care

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Richard Spooner, MD · University of Alberta

  • Yoko Tarumi, MD · University of Alberta/Regional Palliatvie Care Program (Capital Health)

  • Olga Szafran, MSc. · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902031 on ClinicalTrials.gov